The Sunshine Act: What it means to you, what you need to do

Article

The Physician Payments Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

 

Washington-Before the fiscal year goes any farther, this may be a good time to review the newly implemented Physician Payments Sunshine Act, better known simply as the Sunshine Act, which went into effect August 1.

The Sunshine Act is meant to enhance transparency in relationships between the pharmaceutical and drug manufacturing industry and doctors or teaching hospitals. The act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

Manufacturers are required to collect and track payment, transfer, and ownership information. The compiled data is then submitted to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. Also, manufacturers and group purchasing organizations must report certain ownership interests held by doctors and their immediate family members.

Most of the information contained in the reports will be available on a public, searchable Web site starting Q4 2014. Doctors have the right to review their reports and challenge data that are false, inaccurate, or misleading.

To help doctors and the medical community at large navigate this new reporting obligation, the AMA offers a Toolkit for Physician Financial Transparency Reports . The Toolkit is a guide to complying with the process before your 2013 financial data is published online next year.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.